Clinical Trials Browser

gallium Ga 68 dotatate × CNS × 1 year × Clear all

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

Paraganglioma, Pheochromocytoma

NCT04298541 2026-02-27

Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

Phase 2 Not yet recruiting

Meningioma

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04040088 2026-01-08

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Phase EARLY_PHASE1 Active not recruiting

Ganglioneuroma, Neuroblastoma, Ganglioneuroblastoma

NCT07150806 2025-12-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Phase 1/2 Recruiting

Meningioma

NCT04082520 2025-12-11

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Phase 2 Recruiting

Meningioma

NCT06479811 2025-11-25

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Phase 1 Recruiting

CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma